BCTX
BriaCell Therapeutics Corp.
Biotechnology
Market Cap$5M
5Y Perf.-13.3%
Compare Stocks
2 / 10Try these comparisons:
Stock Comparison
BCTX vs CRIS
Revenue, margins, valuation, and 5-year total return — side by side.
CRIS
Curis, Inc.
Biotechnology
Market Cap$74M
5Y Perf.-96.6%
BCTX vs CRIS — Key Financials
Market cap, revenue, margins, and valuation side-by-side.
| Company Snapshot | BCTX | CRIS |
|---|---|---|
| Industry | Biotechnology | Biotechnology |
| Market Cap | $5M | $74M |
| Revenue (TTM) | $0.00 | $9M |
| Net Income (TTM) | $-38M | $-8M |
| Gross Margin | — | 99.5% |
| Operating Margin | — | -348.4% |
| Total Debt | $0.00 | $2M |
| Cash & Equiv. | $14M | $5M |
BCTX vs CRIS — Long-Term Stock Performance
Price return indexed to 100 at period start. Dividends excluded.
BCTX
CRIS
| Stock | May 20 | May 26 | Return |
|---|---|---|---|
| BriaCell Therapeuti… (BCTX) | 100 | 86.7 | -13.3% |
| Curis, Inc. (CRIS) | 100 | 3.4 | -96.6% |
Price return only. Dividends and distributions are not included.
Quick Verdict: BCTX vs CRIS
Each card shows where this stock fits in a portfolio — not just who wins on paper.
Bottom line: CRIS leads in 3 of 6 categories, making it the strongest pick for growth and revenue expansion and recent price momentum and sentiment. BriaCell Therapeutics Corp. is the stronger pick specifically for profitability and margin quality and capital preservation and lower volatility. As sector peers, any of these can serve as alternatives in the same allocation.
BCTX
BriaCell Therapeutics Corp.
The Income Pick
BCTX is the clearest fit if your priority is income & stability and long-term compounding.
- beta 1.56
- -99.1% 5Y total return vs CRIS's -99.7%
- Lower volatility, beta 1.56, current ratio 5.01x
Best for: income & stability and long-term compounding
CRIS
Curis, Inc.
The Growth Play
CRIS carries the broadest edge in this set and is the clearest fit for growth exposure.
- Rev growth -13.4%, EPS growth 91.6%, 3Y rev CAGR -2.4%
- -13.4% revenue growth vs BCTX's -136.6%
- -73.3% vs BCTX's -86.8%
Best for: growth exposure
See the full category breakdown
| Category | Winner | Why |
|---|---|---|
| Growth | CRIS | -13.4% revenue growth vs BCTX's -136.6% |
| Quality / Margins | BCTX | 0.4% margin vs CRIS's -80.3% |
| Stability / Safety | BCTX | Beta 1.56 vs CRIS's 1.92 |
| Dividends | Tie | Neither stock pays a meaningful dividend |
| Momentum (1Y) | CRIS | -73.3% vs BCTX's -86.8% |
| Efficiency (ROA) | CRIS | -26.1% ROA vs BCTX's -153.6% |
BCTX vs CRIS — Revenue Breakdown by Segment
How each company's revenue is distributed across its business units
Segment breakdown not available.
FY 2025
BCTX vs CRIS — Financial Metrics
Side-by-side numbers across 2 stocks — who leads on profitability, valuation, growth, and risk.
BEST OVERALLCRISLAGGINGBCTX
BCTXBriaCell Therapeutics…
0leads
CRISCuris, Inc.
3leads
6 Total Categories
CATEGORYLEADERvs BCTXMETRICS WON
Income & Cash FlowRevenue, margins, and cash flow strength
CRIS1/1
Valuation MetricsMultiples, price ratios, and targets
Tied
—
Profitability & EfficiencyROE, ROIC, leverage, and quality scores
CRIS5/7
Total Returns1Y, 3Y, 5Y total returns with dividends
CRIS3/5
Risk & VolatilityBeta, volatility, and downside exposure
Tied
—
Analyst OutlookRatings, price targets, and dividends
—
—
Income & Cash Flow (Last 12 Months)
CRIS leads this category, winning 1 of 1 comparable metric.
Income & Cash Flow (Last 12 Months)
CRIS and BCTX operate at a comparable scale, with $9M and $0 in trailing revenue.
| Metric | BCTXBriaCell Therapeu… | CRISCuris, Inc. |
|---|---|---|
| RevenueTrailing 12 months | $0 | $9M |
| EBITDAEarnings before interest/tax | -$43M | -$33M |
| Net IncomeAfter-tax profit | -$38M | -$8M |
| Free Cash FlowCash after capex | -$37M | -$27M |
| Gross MarginGross profit ÷ Revenue | — | +99.5% |
| Operating MarginEBIT ÷ Revenue | — | -3.5% |
| Net MarginNet income ÷ Revenue | — | -80.3% |
| FCF MarginFCF ÷ Revenue | — | -2.9% |
| Rev. Growth (YoY)Latest quarter vs prior year | — | -66.0% |
| EPS Growth (YoY)Latest quarter vs prior year | +92.3% | +198.4% |
CRIS leads this category, winning 1 of 1 comparable metric.
Valuation Metrics
Evenly matched — BCTX and CRIS each lead in 1 of 2 comparable metrics.
Valuation Metrics
| Metric | BCTXBriaCell Therapeu… | CRISCuris, Inc. |
|---|---|---|
| Market CapShares × price | $5M | $74M |
| Enterprise ValueMkt cap + debt − cash | -$9M | $70M |
| Trailing P/EPrice ÷ TTM EPS | -0.05x | -0.97x |
| Forward P/EPrice ÷ next-FY EPS est. | — | — |
| PEG RatioP/E ÷ EPS growth rate | — | — |
| EV / EBITDAEnterprise value multiple | — | — |
| Price / SalesMarket cap ÷ Revenue | — | 7.82x |
| Price / BookPrice ÷ Book value/share | 0.33x | 13.52x |
| Price / FCFMarket cap ÷ FCF | — | — |
Evenly matched — BCTX and CRIS each lead in 1 of 2 comparable metrics.
Profitability & Efficiency
CRIS leads this category, winning 5 of 7 comparable metrics.
Profitability & Efficiency
CRIS delivers a -138.8% return on equity — every $100 of shareholder capital generates $-139 in annual profit, vs $-194 for BCTX. On the Piotroski fundamental quality scale (0–9), CRIS scores 3/9 vs BCTX's 1/9, reflecting mixed financial health.
| Metric | BCTXBriaCell Therapeu… | CRISCuris, Inc. |
|---|---|---|
| ROE (TTM)Return on equity | -193.8% | -138.8% |
| ROA (TTM)Return on assets | -153.6% | -26.1% |
| ROICReturn on invested capital | -12.6% | — |
| ROCEReturn on capital employed | -3.4% | -2.3% |
| Piotroski ScoreFundamental quality 0–9 | 1 | 3 |
| Debt / EquityFinancial leverage | — | 0.30x |
| Net DebtTotal debt minus cash | -$14M | -$3M |
| Cash & Equiv.Liquid assets | $14M | $5M |
| Total DebtShort + long-term debt | $0 | $2M |
| Interest CoverageEBIT ÷ Interest expense | -796.67x | -107.35x |
CRIS leads this category, winning 5 of 7 comparable metrics.
Total Returns (Dividends Reinvested)
CRIS leads this category, winning 3 of 5 comparable metrics.
Total Returns (Dividends Reinvested)
A $10,000 investment in BCTX five years ago would be worth $88 today (with dividends reinvested), compared to $29 for CRIS. Over the past 12 months, CRIS leads with a -73.3% total return vs BCTX's -86.8%. The 3-year compound annual growth rate (CAGR) favors CRIS at -67.3% vs BCTX's -84.3% — a key indicator of consistent wealth creation.
| Metric | BCTXBriaCell Therapeu… | CRISCuris, Inc. |
|---|---|---|
| YTD ReturnYear-to-date | -41.6% | -42.8% |
| 1-Year ReturnPast 12 months | -86.8% | -73.3% |
| 3-Year ReturnCumulative with dividends | -99.6% | -96.5% |
| 5-Year ReturnCumulative with dividends | -99.1% | -99.7% |
| 10-Year ReturnCumulative with dividends | — | -99.7% |
| CAGR (3Y)Annualised 3-year return | -84.3% | -67.3% |
CRIS leads this category, winning 3 of 5 comparable metrics.
Risk & Volatility
Evenly matched — BCTX and CRIS each lead in 1 of 2 comparable metrics.
Risk & Volatility
BCTX is the less volatile stock with a 1.56 beta — it tends to amplify market swings less than CRIS's 1.92 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. CRIS currently trades 17.9% from its 52-week high vs BCTX's 11.3% drawdown — a narrower gap to the peak suggests stronger recent price momentum.
| Metric | BCTXBriaCell Therapeu… | CRISCuris, Inc. |
|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | 1.56x | 1.92x |
| 52-Week HighHighest price in past year | $37.20 | $3.13 |
| 52-Week LowLowest price in past year | $3.60 | $0.49 |
| % of 52W HighCurrent price vs 52-week peak | +11.3% | +17.9% |
| RSI (14)Momentum oscillator 0–100 | 48.4 | 43.6 |
| Avg Volume (50D)Average daily shares traded | 183K | 446K |
Evenly matched — BCTX and CRIS each lead in 1 of 2 comparable metrics.
Analyst Outlook
Insufficient data to determine a leader in this category.
Analyst Outlook
| Metric | BCTXBriaCell Therapeu… | CRISCuris, Inc. |
|---|---|---|
| Analyst RatingConsensus buy/hold/sell | — | — |
| Price TargetConsensus 12-month target | — | — |
| # AnalystsCovering analysts | — | — |
| Dividend YieldAnnual dividend ÷ price | — | — |
| Dividend StreakConsecutive years of raises | — | — |
| Dividend / ShareAnnual DPS | — | — |
| Buyback YieldShare repurchases ÷ mkt cap | 0.0% | 0.0% |
Insufficient data to determine a leader in this category.
Key Takeaway
CRIS leads in 3 of 6 categories — strongest in Income & Cash Flow and Profitability & Efficiency. 2 categories are tied.
Best OverallCuris, Inc. (CRIS)Leads 3 of 6 categories
Loading custom metrics...
BCTX vs CRIS: Frequently Asked Questions
7 questions · data-driven answers · updated daily
01Which is the better long-term investment — BCTX or CRIS?
Over the past 5 years, BriaCell Therapeutics Corp.
(BCTX) delivered a total return of -99. 1%, compared to -99. 7% for Curis, Inc. (CRIS). Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
02Which is safer — BCTX or CRIS?
By beta (market sensitivity over 5 years), BriaCell Therapeutics Corp.
(BCTX) is the lower-risk stock at 1. 56β versus Curis, Inc. 's 1. 92β — meaning CRIS is approximately 23% more volatile than BCTX relative to the S&P 500.
03Which is growing faster — BCTX or CRIS?
On earnings-per-share growth, the picture is similar: Curis, Inc.
grew EPS 91. 6% year-over-year, compared to -44. 5% for BriaCell Therapeutics Corp.. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.
04Which has better profit margins — BCTX or CRIS?
BriaCell Therapeutics Corp.
(BCTX) is the more profitable company, earning 0. 0% net margin versus -80. 3% for Curis, Inc. — meaning it keeps 0. 0% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: BCTX leads at 0. 0% versus -348. 4% for CRIS. At the gross margin level — before operating expenses — CRIS leads at 99. 5%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
05Which pays a better dividend — BCTX or CRIS?
None of the stocks in this comparison currently pay a material dividend.
All are effectively zero-yield and should be held for capital appreciation rather than income.
06Is BCTX or CRIS better for a retirement portfolio?
For long-horizon retirement investors, BriaCell Therapeutics Corp.
(BCTX) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding. Curis, Inc. (CRIS) carries a higher beta of 1. 92 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
07What are the main differences between BCTX and CRIS?
Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.
These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
Find Stocks Like These
Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that outperform both.
You Might Also Compare
Based on how these companies actually compete and overlap — not just which sector they're filed under.